Berkeley, Calif. May 11, 2004 New biotech processes are poised to change the economics of manufacturing drugs, creating the potential for delivering both affordable medicines to patients in the developing world and laying the foundation for new markets, according to Victoria Hale, Ph.D., CEO of the Institute for OneWorld Health. The founder of the first nonprofit pharmaceutical company in the U.S. spoke yesterday on a panel, "Synthetic Biology at the Edge" at the 8th International Biotech Summit in Berkeley.
Dr. Hale explained that diseases such as malaria and diarrhea, which are endemic in the developing world, afflict hundreds of millions of people, but affordable medicines are a major barrier to treatment. With advances in biotechnology, industry could achieve humanitarian goals and contribute to strengthening economies that ultimately benefit everyone.
As a step in that direction, malaria medicines will be among the first drugs to be manufactured through an innovative process developed by fellow panelist Jay D. Keasling, Ph.D., Professor of Chemical Engineering at the University of California, Berkeley. Dr. Keasling's team engineered a biotechnology process to make artemisinin, an anti-malarial compound. It is simpler and less expensive than today's laborious plant harvesting processes. This biotech process could be applied to several other kinds of pharmaceutical compounds which are otherwise expensive to synthesize or costly to extract from natural sources.
"By focusing first on the developing world, especially children, a healthier generation leads to greater prosperity, less dependence on foreign aid, and ultimately, creates new markets," Dr. Hale said. "The dynamics for significant change are underway for the private and public sectors, and business community to achieve mutually inclusive goals. We can all participant in and benefit from addressing global health inequities."
The World Health Organization recommends tPage: 1 2 Related biology news :1
Contact: Joanne Hasegawa
Institute for OneWorld Health
. NIH awards $18.2m to The Burnham Institute to develop Center on Proteolytic Pathways2
. Schepens Eye Research Institute receives Roadmap grant to develop center for curing eye diseases3
. The future of HIV therapeutics is brightening, according to Gladstone Institutes Director4
. Institute for OneWorld Health nominated for the 2004 World Technology Awards5
. UNC researchers awarded $8.65 million from National Institute on Aging6
. Institute for OneWorld Health receives Gates Foundation grant7
. Lupus Research Institute awards $3 million in novel research grants to further new science in lupus8
. Virginia Bioinformatics Institute researcher advances fight against sudden oak death disease9
. Institute for OneWorld Health CEO to speak at BIO on leveraging opportunities for global health10
. Institute for Systems Biology, Pacific Northwest National Laboratory announce collaboration11
. Harvard Stem Cell Institute hosts inaugural symposia